Possible Efficacy and Safety of Mebendazole in Patients With Ulcerative Colitis Treated With Mesalamine

Inclusion Criteria:

• Age ≥ 18 years old Both male and female will be included Mild and moderate UC patientsdiagnosed and confirmed by endoscope Patient treated with 5-aminosalislic acid (mesalamine)

Exclusion Criteria:

• • Patients with severe UC
• Significant liver and kidney function abnormalities
• Diabetic patients
• Patients with Colorectal cancer patients
• Patients taking rectal or systemic steroids
• Patients on immunosuppressants or biological therapies
• Addiction to alcohol and / or drugs
• Known allergy to the studied medications
• History of complete or partial colectomy.
• Patients with congestive heart failure, other heart disease (arrhythmia, ischemicheart disease including angina and myocardial infarction).
• Patients with other inflammatory diseases and active infection.
• Patients with stressful condition (COPD, morbid obesity).
• Patients with liver disease.
• Patients with thrombocytopenia and neutropenia.
• Patients with any type of seizures (case report for mebendazole induced convulsion).
• Patients with renal disease (case report for mebendazole induced nephrotoxicity).
• Patients with coagulation disorders.
• Patients on metronidazole (to avoid Stevens-Johnson syndrome).
• Patients with hypersensitivity to mebendazole, albendazole or benzimidazole
• Patients using antioxidants.
• Pregnant and lactating females.
• Patients receiving, metronidazole, warfarin, low dose of aspirin, clopidogril, enzymeinducers (phenytoin, carbamazepine) and inhibitors (valoproate) to avoid potentialpharmacodynamics and pharmacokinetic interactions.